Adding Semaglutide to SGLT2 Inhibitors Reduces Liver Enzymes in Patients with Type 2 Diabetes Complicated by Metabolic Dysfunction Associated Steatotic Liver Disease: A Retrospective Observational Study.

Sato K, Irie Y, Asai H, Yoshioka S, Murakawa K, Sho H, Inui R, Kosugi M, Hazama Y, Yasuda T

Internal medicine (Tokyo, Japan)9 Oct 2025

PMID41062312PMCIDPMC13265098DOI10.2169/internalmedicine.6239-25PepBankPUB-41062312

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and MASLD taking SGLT2 inhibitors, 6 months of semaglutide decreased body weight from baseline.
In plain wordsIn adults with type 2 diabetes and fatty liver, body weight fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 47
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Body weight, before
80.9 kg
baseline
Body weight, after
77.3 kg
6 months
Source sentences
Summary
body weight (BW; 80.9±16.4 kg to 77.3±17.0 kg, p<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231201
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and MASLD taking SGLT2 inhibitors, 6 months of semaglutide decreased body mass index from baseline.
In plain wordsIn adults with type 2 diabetes and fatty liver, body mass index fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBMI change
Study
n = 47
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
body mass index (BMI; 28.9±4.5 kg/m² to 27.7±4.6 kg/m², p<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231202
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and MASLD taking SGLT2 inhibitors, 6 months of semaglutide decreased HbA1c from baseline.
In plain wordsIn adults with type 2 diabetes and fatty liver, blood sugar control (HbA1c) improved after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 47
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
HbA1c, before
7.4%
baseline
HbA1c, after
6.9%
6 months
Source sentences
Summary
glycated hemoglobin (HbA1c; 7.4±0.7% to 6.9±0.7%, p<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231203
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and MASLD taking SGLT2 inhibitors, 6 months of semaglutide decreased AST from baseline.
In plain wordsIn adults with type 2 diabetes and fatty liver, the liver enzyme AST fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseAST change
Study
n = 47
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
AST, before
30.4 U/L
baseline
AST, after
26.3 U/L
6 months
Source sentences
Summary
aspartate aminotransferase (AST; 30.4±15.9 U/L to 26.3±12.5 U/L, p=0.014)
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231204
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and MASLD taking SGLT2 inhibitors, 6 months of semaglutide decreased ALT from baseline.
In plain wordsIn adults with type 2 diabetes and fatty liver, the liver enzyme ALT fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseALT change
Study
n = 47
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
ALT, before
42.4 U/L
baseline
ALT, after
35.7 U/L
6 months
Source sentences
Summary
alanine aminotransferase (ALT; 42.4±28.7 U/L to 35.7±22.8 U/L, p=0.022)
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231205
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and MASLD taking SGLT2 inhibitors, 6 months of semaglutide decreased gamma-glutamyl transpeptidase from baseline.
In plain wordsIn adults with type 2 diabetes and fatty liver, the liver enzyme gamma-GTP fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseGamma-GTP change
Study
n = 47
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
gamma-GTP, before
46.5 U/L
baseline
gamma-GTP, after
38 U/L
6 months
Source sentences
Summary
gamma-glutamyl transpeptidase (γ-GTP; 46.5±36.8 U/L to 38.0±30.0 U/L, p=0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231206
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and MASLD taking SGLT2 inhibitors, the fibrosis-4 index did not improve after 6 months of semaglutide.
In plain wordsIn adults with type 2 diabetes and fatty liver, a liver scarring index did not improve after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
No significant changeFibrosis-4 index change
Study
n = 47
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The fibrosis-4 index, an indicator of liver fibrosis, did not improve.
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231207
08HumanObservational studyMechanism
In adults with type 2 diabetes and MASLD, ALT changes during semaglutide treatment correlated with changes in body weight, BMI, HbA1c and triglycerides.
In plain wordsIn adults with type 2 diabetes and fatty liver, ALT changes on semaglutide were linked to changes in weight, BMI, HbA1c and triglycerides.
Peptide
Semaglutide
Outcome
Not applicableCorrelation of ALT change with metabolic parameter changes
Study
n = 47
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Changes in ALT levels were significantly correlated with changes in metabolic parameters, including BW (p=0.004), BMI (p=0.004), HbA1c (p=0.005), and triglycerides (p=0.011).
2 context sentences(design, population, supporting numbers)
Summary · context
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).
Summary · context
Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.
Report a problemFND-4106231208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Adding Semaglutide to SGLT2 Inhibitors Reduces Liver Enzymes in Patients with Type 2 Diabetes Complicated by Metabolic Dysfunction Associated Steatotic Liver Disease: A Retrospective Observational Study.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords